GEN News Highlights

CellDex to Buy CuraGen in Deal Valued at $94.5M

New deal with CuraGen nets Celldex $54.5M in cash

(Page
1
of
1)

CellDex Therapeutics will acquire CuraGen in a stock-for-stock swap that values Curagen at $94.5 million. The deal, which is expected to close in the third quarter, will combine CellDex' targeted immunotherapy platform with Curagen's antibodies.

Curagen reportedly has 11 fully owned oncology antibodies, one of which is in clinical development. CR011 is currently in Phase II studies in breast cancer and unresectable stage III and IV melanoma. It is also in preclinical development as a treatment for brain tumors.

CellDex is focused on innovative targeted immunotherapeutics for cancer as well as infectious and inflammatory diseases. Its lead candidate, CDX-110, is partnered with Pfizer and is currently undergoing a Phase II trial in newly diagnosed glioblastoma multiforme. Next in line is CDX-1307, which is currently enrolling in a Phase I study in epithelial tumors. CellDex has one clinical candidate in its inflammatory disease program and two in its infectious disease initiative.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

57.3%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.